Evidence map›Paper›PMID 33559085›Full record

ArticleInternational journal of hematology2021

Flow cytometry analysis of peripheral Tregs in patients with multiple myeloma under lenalidomide maintenance.

Kenji Nozaki, Yuki Fujioka, Daisuke Sugiyama, Jun Ishikawa, Masato Iida, Masaru Shibata, Satoru Kosugi, Hiroyoshi Nishikawa, Hirohiko Shibayama

Abstract readLetter
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kenji NozakiDepartment of Hematology and Oncology, Osaka University Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, 565-0871, Japan. knozaki@bldon.med.osaka-u.ac.jp.ORCID http://orcid.org/0000-0002-6208-1227
Yuki FujiokaDepartment of Hematology Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Akita, Japan.
Daisuke SugiyamaDepartment of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Jun IshikawaDepartment of Hematology, Osaka International Cancer Institute, Osaka, Japan.
Masato IidaDepartment of Hematology, Kawasaki Hospital, Kobe, Japan.
Masaru ShibataIkeda City Hospital, Ikeda, Japan.
Satoru KosugiDepartment of Internal Medicine (Hematology), Toyonaka Municipal Hospital, Toyonaka, Japan.
Hiroyoshi NishikawaDivision of Cancer Immunology, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Japan.
Hirohiko ShibayamaDepartment of Hematology and Oncology, Osaka University Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, 565-0871, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdultAgedAntineoplastic AgentsFemaleFlow CytometryHumansLenalidomideMaintenance ChemotherapyMaleMiddle AgedMultiple MyelomaPilot ProjectsT-Lymphocytes, RegulatoryAntineoplastic AgentsLenalidomideFlow cytometryLenalidomideMultiple myelomaRegulatory T cells

Identifiers

PMID33559085

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.